# Jornay PM

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/jornay-pm
Canonical HTML page: https://getbiobrief.com/entity/jornay-pm

## Recent coverage (1 stories)

### Collegium Caps 2025 with Portfolio Pivot; CRAI Signals High Pharma Demand
2026-02-27 14:49:07 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Collegium Pharmaceutical's Q4 2025 results showcase a successful strategic shift toward diversification, led by the ADHD treatment Jornay PM. Simultaneously, CRA International’s earnings highlight a surging demand for specialized life sciences consulting amid a complex regulatory landscape.
Full story: https://getbiobrief.com/story/collegium-pharmaceutical-crai-q4-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.